The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer remains a leading cause of global mortality, with current treatments yielding suboptimal survival rates.
• Cancer immunotherapy has emerged as a powerful strategy, encompassing approaches like CAR-T, CAR-NK cell therapy, and immune checkpoint inhibition.
• Despite advancements, many patients exhibit resistance to immunotherapy, necessitating innovative optimization strategies.

Purpose of the Study:

• To review the development and application of CRISPR/Cas9 technology in cancer immunotherapy.
• To explore how CRISPR/Cas9 can be utilized to overcome immunotherapy resistance.
• To discuss potential challenges associated with combining CRISPR/Cas9 and cancer immunotherapy.

Main Methods:

• Review of existing literature on CRISPR/Cas9 applications in cancer research and immunotherapy.
• Analysis of CRISPR/Cas9's role in enhancing various immunotherapy modalities.
• Examination of CRISPR-based high-throughput screening for drug resistance mechanisms.

Main Results:

• CRISPR/Cas9 is a versatile tool being applied to optimize tumor immunotherapy.
• CRISPR/Cas9 facilitates high-throughput screening for understanding immunomodulatory drug resistance.
• The technology holds potential for improving patient response rates in cancer immunotherapy.

Conclusions:

• CRISPR/Cas9 technology presents significant opportunities for advancing cancer immunotherapy.
• Further research is needed to address potential issues and maximize the benefits of this combined approach.
• Optimizing cancer immunotherapy through genome engineering is a critical area for future cancer treatment development.